Longevity Health Holdings Inc. (Nasdaq: XAGE) has announced that it will continue its listing on the Nasdaq Stock Market as it moves forward with a merger with 20/20 BioLabs, Inc. The company received a favorable decision from the Nasdaq Hearings Panel, allowing it to proceed with the proposed merger, provided it meets Nasdaq's initial listing rules by September 2, 2025. As part of its strategy, Longevity Health Holdings has already filed the S-4 registration statement and completed a 1-for-30 reverse stock split to address listing requirements. The merger aims to enhance the company's focus on extending human longevity through regenerative bio-aesthetics, diagnostics, and nutrition.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。